Steve Warner

Steve Warner

Company: Sumitomo Pharma Oncology

Job title: Senior Vice President & Head of US Research


Exploiting Vulnerabilities in Cancer with Next Generation DDR Inhibitors Targeting Cyclin K or PARG 2:45 pm

Cyclin K degrading molecular glues potentially target CDK12/13-driven expression of DDR genes PARG inhibitors may target homologous recombination deficiencies in cancer in a complementary and differentiated way than PARP inhibitors Targeting Cyclin K or PARG may provide opportunities to inhibit DDR pathways that leverage contextual vulnerabilities in cancer, including CDK12-amplified cancers and PARPi-resistant HRD-positive cancersRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.